Literature DB >> 11439700

Construction of adenoviral vectors.

A R Davis1, N A Wivel, J L Palladino, L Tao, J M Wilson.   

Abstract

Recombinant adenovirus vectors have proven to be useful tools in facilitating gene transfer. Construction of such vectors requires a knowledge of the adenovirus genome structure and its life cycle. A commonly used recombinant adenovirus involves deletion of the E1 region; such a recombinant is traditionally produced by overlap recombination after cotransfection of 293 cells with a plasmid shuttle vector and a large right-end restriction fragment of viral DNA. The shuttle vector contains a cassette for a transgene placed in region E1 and flanking sequences from adenovirus for recombination. Normally, a high background of parental virus results because of the difficulty in separating right-end restriction fragment length DNA from uncut DNA. This paper describes a negative selection based on the traditional cotransfection method using viral DNA from an E1-deleted adenoviral recombinant that expresses green fluorescent protein (GFP). In situ fluorescent microscopy is used to distinguish the recombinant plaques (white or nonfluorescent) from the parental virus plaques (green or fluorescent). In addition, this system allows for the detection of contaminating parental virus at later stages when production lots of the recombinant vector are being made.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11439700     DOI: 10.1385/MB:18:1:63

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  9 in total

1.  High throughput method for creating and screening recombinant adenoviruses.

Authors:  A R Davis; K Meyers; J M Wilson
Journal:  Gene Ther       Date:  1998-08       Impact factor: 5.250

2.  Modified Hirt procedure for rapid purification of extrachromosomal DNA from mammalian cells.

Authors:  U Arad
Journal:  Biotechniques       Date:  1998-05       Impact factor: 1.993

3.  Construction of adenovirus vectors through Cre-lox recombination.

Authors:  S Hardy; M Kitamura; T Harris-Stansil; Y Dai; M L Phipps
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

4.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

Authors:  F L Graham; J Smiley; W C Russell; R Nairn
Journal:  J Gen Virol       Date:  1977-07       Impact factor: 3.891

5.  Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli.

Authors:  C Chartier; E Degryse; M Gantzer; A Dieterle; A Pavirani; M Mehtali
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

6.  An efficient procedure to select and recover recombinant adenovirus vectors.

Authors:  J L Imler; C Chartier; A Dieterlé; D Dreyer; M Mehtali; A Pavirani
Journal:  Gene Ther       Date:  1995-06       Impact factor: 5.250

7.  An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3.

Authors:  A J Bett; W Haddara; L Prevec; F L Graham
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

8.  Efficient manipulation of the human adenovirus genome as an infectious yeast artificial chromosome clone.

Authors:  G Ketner; F Spencer; S Tugendreich; C Connelly; P Hieter
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

9.  Efficient selection of recombinant adenoviruses by vectors that express beta-galactosidase.

Authors:  J Schaack; S Langer; X Guo
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

  9 in total
  9 in total

Review 1.  Targeting calcium cycling proteins in heart failure through gene transfer.

Authors:  Federica del Monte; Roger J Hajjar
Journal:  J Physiol       Date:  2003-01-01       Impact factor: 5.182

2.  Adenoviral vector-mediated overexpression of osteoprotegerin accelerates osteointegration of titanium implants in ovariectomized rats.

Authors:  G Yin; J Chen; S Wei; H Wang; Q Chen; Y Lin; J Hu; E Luo
Journal:  Gene Ther       Date:  2015-04-14       Impact factor: 5.250

3.  Hydrogel microsphere encapsulation of a cell-based gene therapy system increases cell survival of injected cells, transgene expression, and bone volume in a model of heterotopic ossification.

Authors:  Ronke M Olabisi; Zawaunyka W Lazard; Christy L Franco; Mary A Hall; Sun Kuk Kwon; Eva M Sevick-Muraca; John A Hipp; Alan R Davis; Elizabeth A Olmsted-Davis; Jennifer L West
Journal:  Tissue Eng Part A       Date:  2010-09-01       Impact factor: 3.845

4.  An injectable method for noninvasive spine fusion.

Authors:  Ronke M Olabisi; ZaWaunyka Lazard; Michael H Heggeness; Kevin M Moran; John A Hipp; Ashvin K Dewan; Alan R Davis; Jennifer L West; Elizabeth A Olmsted-Davis
Journal:  Spine J       Date:  2011-02-02       Impact factor: 4.166

Review 5.  Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens.

Authors:  Sam Afkhami; Yushi Yao; Zhou Xing
Journal:  Mol Ther Methods Clin Dev       Date:  2016-04-27       Impact factor: 6.698

6.  Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients.

Authors:  Hua Zhao; Can Xu; Xiaoli Luo; Feng Wei; Ning Wang; Huiying Shi; Xiubao Ren
Journal:  Front Immunol       Date:  2018-03-07       Impact factor: 7.561

7.  Effects of simian virus 40 large and small tumor antigens on mammalian target of rapamycin signaling: small tumor antigen mediates hypophosphorylation of eIF4E-binding protein 1 late in infection.

Authors:  Yongjun Yu; Sagar B Kudchodkar; James C Alwine
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

8.  A novel helper-dependent adenovirus-based cell culture model for Hepatitis C virus replication and production.

Authors:  Xiaojun Zhou; Yang Zeng; Junfeng Li; Yan Guo; Yuanhui Fu; Jinsheng He; Shihui Sun; Yusen Zhou
Journal:  Virol J       Date:  2013-08-30       Impact factor: 4.099

Review 9.  Adenoviruses as vaccine vectors.

Authors:  Nia Tatsis; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2004-10       Impact factor: 11.454

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.